Source: Benzinga

Ultragenyx: Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 6, 2025, to discuss its financial results and corporate update for the quarter ending March 31, 2025.The live and replayed ...Full story available on Benzinga.com

Read full article »
Annual Revenue
$500M-1.0B
Employees
1.0-5.0K
Emil D. Kakkis's photo - President & CEO of Ultragenyx

President & CEO

Emil D. Kakkis

CEO Approval Rating

83/100

Read more